AMARIN CORP PLC\UK Current Assets
AMARIN CORP PLC\UK (AMRN) had Current Assets of $602.76 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-07-29
- 2026-06-30: Assets, Current $602.76M.
- 2026-03-31: Assets, Current $626.02M.
- 2025-12-31: Assets, Current $649.88M.
- 2025-09-30: Assets, Current $628.33M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $602.76M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $626.02M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $649.88M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $628.33M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $606.82M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $573.06M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $595.40M 10-K · filed 2026-03-02 |
| 2024-09-30 | $650.22M 10-Q · filed 2024-10-30 |
| 2024-06-30 | $701.84M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $687.93M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $724.98M 10-K · filed 2025-03-12 |
| 2023-09-30 | $717.51M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $706.50M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $683.82M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $689.10M 10-K · filed 2024-02-29 |
| 2022-09-30 | $686.52M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $719.12M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $772.62M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $878.73M 10-K · filed 2023-03-01 |
| 2021-09-30 | $963.03M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $995.98M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $930.52M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $879.23M 10-K · filed 2022-03-01 |
| 2020-09-30 | $888.54M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $827.61M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $817.31M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $855.00M 10-K · filed 2021-02-25 |
| 2019-09-30 | $848.11M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $372.04M 10-Q · filed 2019-07-31 |
| 2019-03-31 | $355.32M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $378.00M 10-K · filed 2020-02-25 |
| 2018-09-30 | $202.40M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $196.14M 10-Q · filed 2018-08-01 |
| 2018-03-31 | $207.55M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $153.27M 10-K · filed 2019-02-27 |
| 2017-09-30 | $147.03M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $150.43M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $154.79M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $146.33M 10-K · filed 2018-02-27 |
| 2016-09-30 | $161.18M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $116.51M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $124.43M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $143.52M 10-K · filed 2017-03-01 |
| 2015-09-30 | $156.14M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $169.33M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $189.75M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $145.28M 10-K · filed 2016-02-25 |
| 2014-09-30 | $158.04M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $177.98M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $194.15M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $219.40M 10-K · filed 2015-03-03 |
| 2013-09-30 | $262.56M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $184.71M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $242.04M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $285.69M 10-K · filed 2014-02-27 |
| 2012-09-30 | $228.74M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $257.22M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $251.32M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $118.97M 10-K · filed 2013-02-28 |
| 2011-09-30 | $128.07M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $132.58M 10-Q · filed 2011-08-09 |
| 2010-12-31 | $33.11M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |